P

Philips

Makes medical devices and personal health products

Director – Process Compliance & Centers of Excellence

Full-TimeUpdated on 10/15/2026
€93k - €155k
Expert
Bachelor's, Master's, MBA
Best, Netherlands
HybridOffice-based role requiring at least three days per week in person.
Manufacturing Quality & TestValidation, Compliance & Quality Systems

About the job

Requirements
  • A minimum of 10 years of experience in FDA-regulated medical device environments, with extensive focus on Quality Management System compliance, Corrective and Preventive Action processes, internal audits, and process or continuous improvement.
  • A minimum of 5 years of experience in functional or strategic leadership of quality teams or organizations within global, matrixed organizations.
  • Robust understanding and deep knowledge of FDA 21 CFR Part 820, ISO 13485, the European Union Medical Device Regulation, and other global medical device standards.
  • Detailed knowledge of Risk Management (ISO 14971), Process Failure Mode and Effects Analysis, root cause analysis, and design transfer activities.
  • Extensive experience leading or supporting regulatory inspections by the FDA and Notified Bodies.
  • Proven experience leading strategic process validation initiatives, Corrective and Preventive Action processes, Non-Conformances, and Quality Notifications.
  • A bachelor's degree in Engineering, Life Sciences, or a related technical field is required.
  • Ability to successfully perform the minimum physical, cognitive, and environmental job requirements with or without accommodation.
Responsibilities
  • Spearhead the strategic development and deployment of robust enterprise quality controls and process improvements.
  • Lead organization-wide compliance initiatives, proactively drive integration of new tools and processes, and analyze data for trends and risks.
  • Drive strategic initiatives to elevate supplier quality standards, collaborating with cross-functional teams in Research and Development, manufacturing, and regulatory affairs to address process gaps and maintain quality benchmarks.
  • Guide the setup of acceptance activities, including transfer to manufacturing; resolve process deficiencies; and develop New Product Introduction validations, process development, process controls, inspection plans, and control plans.
  • Collaborate with the Quality Optimization team to integrate initiatives into site Quality Management System processes.
  • Analyze data to identify trends, risks, and improvement opportunities, and proactively support process improvement.
  • Drive cost reduction and productivity through analysis of Cost of Poor Quality data and assist teams with implementing cost-saving initiatives.
  • Manage compliance with industry regulations and oversee the preparation and maintenance of documentation.
  • Lead talent management and succession planning, and develop a high-performing team aligned with organizational goals.
  • Authorize assessment of the impact of design changes on Process Failure Mode and Effects Analysis and associated controls, and assist with Manufacturing Process Development and Design Transfer activities.
  • Mentor quality engineers and cultivate continuous learning and knowledge sharing, supporting New Product Introduction projects and product transfers within the manufacturing facility.
  • Lead succession planning and comprehensive talent management, including employee selection, performance management, compensation management, and career development in alignment with organizational operational goals.
  • Travel up to 25% domestically and internationally.
Desired Qualifications
  • A master's degree (MBA, MS, or equivalent) is preferred.

About the company

Philips makes medical equipment and software for hospitals and care providers, along with personal health products for consumers. Its hospital portfolio spans MRI and CT scanners, ultrasound, image-guided treatment systems and patient monitors, while Sonicare and Avent cover oral health and baby care. Clinical software connects medical images and patient data across care teams, and the company earns revenue from equipment, software, maintenance and consumer product sales. It works with health systems through long-term technology and service partnerships, including solutions for care at home. Founded in 1891, Philips is headquartered in Amsterdam, the Netherlands.

Company Size

10,001+

Company Stage

IPO

Headquarters

Andover, Minnesota

Founded

1891

Get referred to Philips

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand improved: Philips reported 4% comparable group sales growth for Q2 2026 in July 2026.
  • Software expertise has room to develop: software and data science comprised about half Philips' research effort in 2025.
  • Manufacturing expansion has backing: Philips reiterated a $150 million North American investment plan in February 2026.

What critics are saying

  • US sleep-device sales remain restricted: Philips Respironics must meet consent-decree requirements before resuming new sleep-therapy device sales.
  • Underlying earnings weakened: Philips' July 2026 report shows Q2 adjusted earnings fell slightly excluding its US tariff refund.
  • Central teams face cost pressure: February 2026 plans target 15% to 20% lower central-function costs at Philips.

What makes Philips unique

  • MRI avoids helium refills: Philips says its sealed BlueSeal magnets use seven liters rather than conventional systems' 1,500.
  • Inventions form a substantial asset base: Philips reports 53,000 patent rights across its technology portfolio.
  • The employer's name spans independent businesses: Philips licenses its brands across multiple product categories to outside partners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Health Savings Account/Flexible Spending Account

Company News

PR Newswire
May 28th, 2026
Remote patient monitoring market to reach $117.9B by 2033 amid digital healthcare transformation

The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.

HIT Consultant
Apr 12th, 2024
Philips Respironics Reaches Final Agreement With Us Regulators On Sleep Apnea Device Recall

<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US,  subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024.  The company’s previously announced 2023-2025 financial outlook remains unchanged,  already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more

Goodrich Pharmacy
Jan 29th, 2024
Phillips Suspends U.S. Sales of CPAP, Ventilator Machines After Recall

Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.

YourLawyer.com
Mar 23rd, 2023
Sleep Apnea Patients Suffer While Waiting To Receive Their Repaired Philips CPAP Machines

In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.

Digital Journal
Jan 13th, 2023
Ultrasound Market Share | Market | Report | Analysis 2032 | Key Players: Fujifilm Holdings Corporation, Analogic Corporation, Siemens Healthcare among others

February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.